Chronic Resveratrol Treatment Protects Pancreatic Islets against Oxidative Stress in db/db Mice

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Lee, Young Eun ^a   Kim, Ji Won ^a   Lee, Eun Mi ^a   Ahn, Yu Bae ^a   Song, Ki Ho ^a   Yoon, Kun Ho ^a   Kim, Hyung Wook ^a   Park, Cheol Whee ^a   Li, Guolian ^b   Liu, Zhenqi ^b   Ko, Seung Hyun ^a  

^a The Catholic University of Korea   (South Korea)

^b UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEPTIN RECEPTOR; RESVERATROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOTINYLATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; GLUCOSE TOLERANCE TEST; IMMUNOHISTOCHEMISTRY; INSULIN SENSITIVITY; INSULIN TOLERANCE TEST; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORGAN WEIGHT; OXIDATIVE STRESS; PANCREAS ISLET CELL; POINT MUTATION; TREATMENT DURATION; TREATMENT RESPONSE;

ANIMALS; ANTIOXIDANTS; BLOOD GLUCOSE; DEOXYGUANOSINE; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; FIBROSIS; GLUCOSE TOLERANCE TEST; IMMUNOHISTOCHEMISTRY; INSULIN; INSULIN RESISTANCE; ISLETS OF LANGERHANS; MALE; MICE; ORGAN SIZE; OXIDATIVE STRESS; STILBENES;

ANIMALIA; MUS; RICE STRIPE VIRUS;

EID: 84870605931     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0050412     Document Type: Article

References (52)

1. Shulman GI, (2000) Cellular mechanisms of insulin resistance. J Clin Invest 106: 171-176.
2. Weyer C, Bogardus C, Mott DM, Pratley RE, (1999) The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 104: 787-794.
3. Drews G, Krippeit-Drews P, Düfer M, (2010) Oxidative stress and beta-cell dysfunction. Pflugers Arch 460: 703-718.
4. Henriksen EJ, Diamond-Stanic MK, Marchionne EM, (2011) Oxidative stress and the etiology of insulin resistance and type 2 diabetes. Free Radic Biol Med 51: 993-999.
5. Evans JL, Goldfine ID, Maddux BA, Grodsky GM, (2002) Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev 23: 599-622.
6. Rains JL, Jain SK, (2011) Oxidative stress, insulin signaling, and diabetes. Free Radic Biol Med 50: 567-575.
7. Kaneto H, Matsuoka TA, Nakatani Y, Kawamori D, Miyatsuka T, et al. (2005) Oxidative stress, ER stress, and the JNK pathway in type 2 diabetes. J Mol Med (Berl) 83: 429-439.
8. Frémont L, (2000) Biological effects of resveratrol. Life Sci 66: 663-673.
9. Baur JA, Sinclair DA, (2006) Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 5: 493-506.
10. Wenzel E, Somoza V, (2005) Metabolism and bioavailability of trans-resveratrol. Mol Nutr Food Res 49: 472-481.
11. Di Castelnuovo A, Rotondo S, Iacoviello L, Donati MB, De Gaetano G, (2002) Meta-analysis of wine and beer consumption in relation to vascular risk. Circulation 105: 2836-2344.
12. Renaud S, de Lorgeril M, (1992) Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet 339: 1523-1526.
13. Das DK, Maulik N, (2006) Resveratrol in cardioprotection: a therapeutic promise of alternative medicine. Mol Interv 6: 36-47.
14. Cucciolla V, Borriello A, Oliva A, Galletti P, Zappia V, et al. (2007) Resveratrol: from basic science to the clinic. Cell Cycle 6: 2495-2510.
15. de la Lastra CA, Villegas I, (2007) Resveratrol as an antioxidant and pro-oxidant agent: mechanisms and clinical implications. Biochem Soc Trans 35(Pt5): 1156-1560.
16. Ungvari Z, Orosz Z, Rivera A, Labinskyy N, Xiangmin Z, et al. (2007) Resveratrol increases vascular oxidative stress resistance. Am J Physiol Heart Circ Physiol 292: H2417-H2424.
17. Rivera L, Morón R, Zarzuelo A, Galisteo M, (2009) Long-term resveratrol administration reduces metabolic disturbances and lowers blood pressure in obese Zucker rats. Biochem Pharmacol 77: 1053-1063.
18. Palsamy P, Subramanian S, (2010) Ameliorative potential of resveratrol on proinflammatory cytokines, hyperglycemia mediated oxidative stress, and pancreatic beta-cell dysfunction in streptozotocin-nicotinamide-induced diabetic rats. J Cell Physiol 224: 423-432.
19. Szkudelski T, Szkudelska K, (2011) Anti-diabetic effects of resveratrol. Ann NY Acad Sci 1215: 34-39.
20. Chen H, Charlat O, Tartaglia LA, Woolf EA, Weng X, et al. (1996) Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice. Cell 84: 491-495.
21. Sallam N, Fisher A, Golbidi S, Laher I, (2011) Weight and inflammation are the major determinants of vascular dysfunction in the aortae of db/db mice. Naunyn Schmiedebergs Arch Pharmacol. 383: 483-492.
22. Zhang H, Zhang J, Ungvari Z, Zhang C, (2009) Resveratrol improves endothelial function: role of TNF{alpha} and vascular oxidative stress. Arterioscler Thromb Vasc Biol 29: 1164-1171.
23. Um JH, Park SJ, Kang H, Yang S, Foretz M, et al. (2010) AMP-activated protein kinase-deficient mice are resistant to the metabolic effects of resveratrol. Diabetes 59: 554-563.
24. Weibel ER (1978) Stereologic methods. In practical Methods for Biologic Morphometry, Vol. 1, London, Academic Press. 101 p.
25. Bonner-Weir S, (2001) β-cell turnover: Its assessment and implications. Diabetes 50 (suppl (1):: S20-S24.
26. Broedbaek K, Weimann A, Stovgaard ES, Poulsen HE, (2011) Urinary 8-oxo-7,8-dihydro-2′-deoxyguanosine as a biomarker in type 2 diabetes. Free Radic Biol Med 51: 1473-1479.
27. Clark A, Jones LC, de Koning E, Hansen BC, Matthews DR, (2001) Decreased insulin secretion in type 2 diabetes: A problem of cellular mass or function? Diabetes 50(suppl (1):: S169-S171.
28. Leahy JL, Bonner-Weir S, Weir GC, (1992) Beta cell dysfunction induced by chronic hyperglycemia. Diabetes Care 15: 442-455.
29. Shakibaei M, Harikumar KB, Aggarwal BB, (2009) Resveratrol addiction: to die or not to die. Mol Nutr Food Res 53: 115-128.
30. Su HC, Hung LM, Chen JK, (2006) Resveratrol, a red wine antioxidant, possesses an insulin-like effect in streptozotocin-induced diabetic rats. Am J Physiol Endocrinol Metab 290: E1339-1346.
31. Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, et al. (2006) Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 127: 1109-1122.
32. Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, et al. (2006) Resveratrol improves health and survival of mice on a high-calorie diet. Nature 444: 337-342.
33. Rahman I, Biswas SK, Kirkham PA, (2006) Regulation of inflammation and redox signaling by dietary polyphenols. Biochemical Pharmacology 72: 1439-1452.
34. Sharma S, Misra CS, Arumugam S, Roy S, Shah V, et al. (2011) Antidiabetic activity of resveratrol, a known SIRT1 activator in a genetic model for type 2 diabetes. Phytother Res 25: 67-73.
35. Leonard SS, Xia C, Jiang BH, Stinefelt B, Klandorf H, et al. (2003) Resveratrol scavenges reactive oxygen species and effects radical-induced cellular responses. Biochem Biophys Res Commun 309: 1017-1026.
36. Chow SE, Hshu YC, Wang JS, Chen JK, (2007) Resveratrol attenuates oxLDL-stimulated NADPH oxidase activity and protects endothelial cells from oxidative functional damages. J Appl Physiol 102: 1520-1527.
37. Minakawa M, Kawano A, Miura Y, Yagasaki K, (2011) Hypoglycemic effect of resveratrol in type 2 diabetic model db/db mice and its actions in cultured L6 myotubes and RIN-5F pancreatic β-cells. J Clin Biochem Nutr 48: 237-244.
38. Delmas D, Jannin B, Latruffe N, (2005) Resveratrol: preventing properties against vascular alterations and ageing. Mol Nutr Food Res 49: 377-395.
39. Cavallaro A, Ainis T, Bottari C, Fimiani V, (2003) Effect of resveratrol on some activities of isolated and in whole blood human neutrophils. Physiol Res 52: 555-562.
40. Kitada M, Kume S, Imaizumi N, Koya D, (2011) Resveratrol improves oxidative stress and protects against diabetic nephropathy through normalization of Mn-SOD dysfunction in AMPK/SIRT1-independent pathway. Diabetes 60: 634-643.
41. Lee EM, Lee YE, Lee E, Ryu GR, Ko SH, et al. (2011) Protective Effect of Heme Oxygenase-1 on High Glucose-Induced Pancreatic β-Cell Injury. Diabetes Metab J 35: 469-479.
42. Dandona P, Thusu K, Cook S, Snyder B, Makowski J, et al. (1996) Oxidative damage to DNA in diabetes mellitus. Lancet 347: 444-445.
43. Sakuraba H, Mizukami H, Yagihashi N, Wada R, Hanyu C, et al. (2002) Reduced beta-cell mass and expression of oxidative stress-related DNA damage in the islet of Japanese Type II diabetic patients. Diabetologia 45: 85-96.
44. Lee E, Ryu GR, Ko SH, Ahn YB, Yoon KH, et al. (2011) Antioxidant treatment may protect pancreatic beta cells through the attenuation of islet fibrosis in an animal model of type 2 diabetes. Biochem Biophys Res Commun 414: 397-402.
45. Tanaka Y, Gleason CE, Tran PO, Harmon JS, Robertson RP, (1999) Prevention of glucose toxicity in HIT-T15 cells and Zucker diabetic fatty rats by antioxidants. Proc. Natl. Acad. Sci. USA 96: 10857-10862.
46. Huang A, Yang YM, Feher A, Bagi Z, Kaley G, Sun D, (2012) Exacerbation of endothelial dysfunction during the progression of diabetes: role of oxidative stress. Am J Physiol Regul Integr Comp Physiol. 302(6): R674-81.
47. Poitout V, Robertson RP, (2008) Glucolipotoxicity: fuel excess and beta-cell dysfunction. Endocr Rev 29: 351-366.
48. Robertson RP, Harmon JS, (2006) Diabetes, glucose toxicity, and oxidative stress: A case of double jeopardy for the pancreatic islet beta cell. Free Radic Biol Med 41: 177-184.
49. Kaneto H, Kajimoto Y, Miyagawa J, Matsuoka T, Fujitani Y, et al. (1999) Beneficial effects of antioxidants in diabetes: possible protection of pancreatic beta-cells against glucose toxicity. Diabetes 48: 2398-2406.
50. Robertson RP, (2004) Chronic oxidative stress as a central mechanism for glucose toxicity in pancreatic islet beta cells in diabetes. J Biol Chem 279: 42351-42354.
51. Vetterli L, Brun T, Giovannoni L, Bosco D, Maechler P, (2011) Resveratrol potentiates glucose-stimulated insulin secretion in INS-1E beta-cells and human islets through a SIRT1-dependent mechanism. J Biol Chem 286: 6049-6060.
52. Szkudelski T, (2007) Resveratrol-induced inhibition of insulin secretion from rat pancreatic islets: evidence for pivotal role of metabolic disturbances. Am J Physiol Endocrinol Metab 293: E901-907.